Samjin Pharmaceuticals Co., Ltd. (005500.KS)

KRW 18280.0

(-0.33%)

Market Cap (In KRW)

229 Billion

Revenue (In KRW)

292.12 Billion

Net Income (In KRW)

18.9 Billion

Avg. Volume

15.52 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16690.0-22700.0
PE
-
EPS
-
Beta Value
0.266
ISIN
KR7005500004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yong-Joo Choi
Employee Count
-
Website
https://www.samjinpharm.co.kr
Ipo Date
2005-09-29
Details
Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.

More Stocks